CN113330037A - 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 - Google Patents

二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 Download PDF

Info

Publication number
CN113330037A
CN113330037A CN201980078998.8A CN201980078998A CN113330037A CN 113330037 A CN113330037 A CN 113330037A CN 201980078998 A CN201980078998 A CN 201980078998A CN 113330037 A CN113330037 A CN 113330037A
Authority
CN
China
Prior art keywords
antibody
heavy chain
antigen
specifically binds
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980078998.8A
Other languages
English (en)
Other versions
CN113330037B (zh
Inventor
冯晓
金磊
王涛
郭洪瑞
刘爽
陈宇珩
韩宁
梁阳秋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GeneScience Pharmaceuticals Co Ltd
Original Assignee
GeneScience Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GeneScience Pharmaceuticals Co Ltd filed Critical GeneScience Pharmaceuticals Co Ltd
Publication of CN113330037A publication Critical patent/CN113330037A/zh
Application granted granted Critical
Publication of CN113330037B publication Critical patent/CN113330037B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物。该二价双特异性抗体包括：a)特异性结合第一抗原的抗体的单链可变片段scFv、柔性肽、重链IgG1恒定区CH1以及铰链区部分序列，和b)特异性结合第二抗原的抗体的单链可变片段scFv和轻链恒定区CL，即scFv1‑CL或CL‑scFv1；或者包括：c)特异性结合第一抗原的抗体的轻链和重链；和d)特异性结合第二抗原的抗体的轻链和重链。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN201980078998.8A 2018-12-28 2019-12-26 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 Active CN113330037B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811622069.2A CN111378045B (zh) 2018-12-28 2018-12-28 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
CN2018116220692 2018-12-28
PCT/CN2019/128582 WO2020135555A1 (zh) 2018-12-28 2019-12-26 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物

Publications (2)

Publication Number Publication Date
CN113330037A true CN113330037A (zh) 2021-08-31
CN113330037B CN113330037B (zh) 2023-05-12

Family

ID=71128676

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811622069.2A Active CN111378045B (zh) 2018-12-28 2018-12-28 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
CN201980078998.8A Active CN113330037B (zh) 2018-12-28 2019-12-26 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811622069.2A Active CN111378045B (zh) 2018-12-28 2018-12-28 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物

Country Status (5)

Country Link
US (1) US20220073610A1 (zh)
EP (1) EP3904392A4 (zh)
JP (1) JP7312834B2 (zh)
CN (2) CN111378045B (zh)
WO (1) WO2020135555A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111378045B (zh) * 2018-12-28 2022-08-02 长春金赛药业有限责任公司 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515509A (ja) * 2009-12-29 2013-05-09 エマージェント プロダクト デベロップメント シアトル， エルエルシー ヘテロダイマー結合タンパク質およびその使用
CN104558193A (zh) * 2015-01-21 2015-04-29 武汉友芝友生物制药有限公司 一种靶向鼠t淋巴细胞cd3和人肿瘤抗原her2的双特异性抗体制备方法及应用
CN106084052A (zh) * 2016-06-17 2016-11-09 长春金赛药业有限责任公司 抗cd47单克隆抗体及其应用
CN107459578A (zh) * 2016-05-31 2017-12-12 泰州迈博太科药业有限公司 一种靶向cd47与pd‑l1的双功能融合蛋白
WO2018090950A1 (zh) * 2016-11-18 2018-05-24 北京韩美药品有限公司 抗pd‐1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
CN108250296A (zh) * 2018-01-17 2018-07-06 长春金赛药业股份有限公司 全人源抗人pd-l1单克隆抗体及其应用
CN111378045B (zh) * 2018-12-28 2022-08-02 长春金赛药业有限责任公司 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
SG187682A1 (en) * 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
KR20130133247A (ko) * 2010-12-21 2013-12-06 애브비 인코포레이티드 Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
CN102586323B (zh) * 2011-07-22 2014-03-26 长春金赛药业有限责任公司 靶向免疫融合蛋白的构建、表达和纯化方法
CN107586340B (zh) 2011-08-23 2022-01-21 罗切格利卡特公司 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
CN112079929A (zh) 2012-11-21 2020-12-15 武汉友芝友生物制药有限公司 双特异性抗体
CN113559258A (zh) 2015-02-04 2021-10-29 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CN107759694B (zh) * 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN108659112B (zh) * 2017-03-30 2021-01-26 上海市同济医院 一种非对称双特异性抗体
CN108640997A (zh) * 2018-05-22 2018-10-12 蔡毓旻 一种双特异性抗体

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515509A (ja) * 2009-12-29 2013-05-09 エマージェント プロダクト デベロップメント シアトル， エルエルシー ヘテロダイマー結合タンパク質およびその使用
CN104558193A (zh) * 2015-01-21 2015-04-29 武汉友芝友生物制药有限公司 一种靶向鼠t淋巴细胞cd3和人肿瘤抗原her2的双特异性抗体制备方法及应用
CN107459578A (zh) * 2016-05-31 2017-12-12 泰州迈博太科药业有限公司 一种靶向cd47与pd‑l1的双功能融合蛋白
CN106084052A (zh) * 2016-06-17 2016-11-09 长春金赛药业有限责任公司 抗cd47单克隆抗体及其应用
WO2018090950A1 (zh) * 2016-11-18 2018-05-24 北京韩美药品有限公司 抗pd‐1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
CN108250296A (zh) * 2018-01-17 2018-07-06 长春金赛药业股份有限公司 全人源抗人pd-l1单克隆抗体及其应用
CN111378045B (zh) * 2018-12-28 2022-08-02 长春金赛药业有限责任公司 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTOPH SPIESS等: "Alternative molecular formats and therapeutic applications for Alternative molecular formats and therapeutic applications for bispecific antibodies", 《MOLECULAR IMMUNOLOGY》 *
K M MÜLLER等: "The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies", 《FEBS LETT》 *
ULRICH BRINKMANN等: "The making of bispecific antibodies", 《MABS》 *
邵长利等: "基于柔性肽连接的双特异性抗体分子的设计与结构模拟", 《免疫学杂志》 *

Also Published As

Publication number Publication date
JP7312834B2 (ja) 2023-07-21
EP3904392A4 (en) 2022-12-07
WO2020135555A1 (zh) 2020-07-02
EP3904392A1 (en) 2021-11-03
CN111378045A (zh) 2020-07-07
CN111378045B (zh) 2022-08-02
JP2022517549A (ja) 2022-03-09
US20220073610A1 (en) 2022-03-10
CN113330037B (zh) 2023-05-12

Similar Documents

Publication Publication Date Title
CN113015749B (zh) 靶向cd3的抗体、双特异性抗体及其用途
US9315576B2 (en) Antigen binding polypeptides
US9540437B2 (en) Humanized antibodies
CN103068846B9 (zh) 包含二硫键稳定性Fv片段的双特异性抗体
KR101266659B1 (ko) ２가, 이중특이적 항체
JP5501439B2 (ja) 完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
RU2570633C2 (ru) Три- или тетраспецифические антитела
KR101249607B1 (ko) 2가, 이중특이적 항체
KR101265855B1 (ko) 2가, 이중특이적 항체
CN113330037B (zh) 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
RU2808138C1 (ru) Антитело, нацеливающееся на cd3, биспецифическое антитело и их применение
WO2022156739A1 (zh) 特异性结合bcma和cd3的抗原结合分子及其医药用途
WO2023051680A1 (zh) 针对免疫检查点的双特异性抗体
WO2023161448A1 (en) Human-like target-binding proteins
CN117820481A (zh) 新型抗体分子及其制药用途
IL210002A (en) Polypeptides that bind to antigen

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant